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Abstract
Background: Reproducibly high transfection rates with low methodology-induced cytotoxic side effects are
essential to attain the required effect on targeted cells when exogenous DNA is transfected. Different approaches
and modifications such as the use of nanoparticles (NPs) are being evaluated to increase transfection efficiencies.
Several studies have focused on the attained transfection efficiency after NP-mediated approaches. However, data
comparing toxicity of these novel approaches with conventional methods is still rare.
Transfection efficiency and methodology-induced cytotoxicity were analysed after transfection with different
NP-mediated and conventional approaches. Two eukaryotic DNA-expression-plasmids were used to transfect the
mammalian cell line MTH53A applying six different transfection protocols: conventional transfection reagent
(FuGENE HD, FHD), FHD in combination with two different sizes of stabilizer-free laser-generated AuNPs (PLAL-
AuNPs_S1,_S2), FHD and commercially available AuNPs (Plano-AuNP), and two magnetic transfection protocols.
24 h post transfection efficiency of each protocol was analysed using fluorescence microscopy and GFP-based flow
cytometry. Toxicity was assessed measuring cell proliferation and percentage of propidium iodide (PI%) positive
cells. Expression of the respective recombinant proteins was evaluated by immunofluorescence.
Results: The addition of AuNPs to the transfection protocols significantly increased transfection efficiency in the
pIRES-hrGFPII-eIL-12 transfections (FHD: 16%; AuNPs mean: 28%), whereas the magnet-assisted protocols did not
increase efficiency. Ligand-free PLAL-AuNPs had no significant cytotoxic effect, while the ligand-stabilized Plano-
AuNPs induced a significant increase in the PI% and lower cell proliferation. For pIRES-hrGFPII-rHMGB1 transfections
significantly higher transfection efficiency was observed with PLAL-AuNPs (FHD: 31%; PLAL-AuNPs_S1: 46%; PLAL-
AuNPs_S2: 50%), while the magnet-assisted transfection led to significantly lower efficiencies than the FHD
protocol. With PLAL-AuNPs_S1 and _S2 the PI% was significantly higher, yet no consistent effect of these NPs on
cell proliferation was observed. The magnet-assisted protocols were least effective, but did result in the lowest
cytotoxic effect.
Conclusions: This study demonstrated that transfection efficiency of DNA-expression-plasmids was significantly
improved by the addition of AuNPs. In some combinations the respective cytotoxicity was increased depending on
the type of the applied AuNPs and the transfected DNA construct. Consequently, our results indicate that for
routine use of these AuNPs the specific nanoparticle formulation and DNA construct combination has to be
considered.
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Transfection of eukaryotic cells is a key technology in cell
biology being used in several areas of basic and therapeutic
research. The critical points in these experimental
approaches are the achieved transfection efficiencies and
the reproducibility of the performed experiments. There-
fore, a stable high transfection rate with low methodology
induced side effects in terms of toxicity would be desir-
able. Furthermore, the methods used should not interfere
with the functionality of the delivered molecules such as
large DNA expression plasmids or small RNAs such as
siRNAs and miRNAs.
Currently, several non-viral transfection methods for
eukaryotic cells are used to introduce membrane imperme-
able molecules into the cells. However, the efficiency, toxi-
city, and reproducibility, which may vary depending on the
characteristics of the cells used, remain a crucial aspect in
cell transfection. Consequently, various methods and modi-
fications are currently being evaluated to increase efficiency
and reduce toxicity. Thus, both novel laser-based transfec-
tion methods [1] as well as nanoparticle (NP) approaches
have been evaluated in recent studies [2-4]. Considering
the latter, gold Nanoparticles (AuNPs) are in the focus of
intense research due to their chemical stability, electro-
density and -affinity to biomolecules such as DNA, when
these AuNPs are charged [5]. However, the inherent char-
acteristics of the applied NPs could induce different toxic
effects on cells due to several factors such as particle num-
ber and size, surface dose, surface coatings, degree of
agglomeration, surface charges on particles and method of
particle synthesis as well as post-synthetic modifications.
During or after most forms of NP synthesis, the generated
NPs are modified to prevent aggregation or induce disag-
gregation. The surface modification and surface charge can
have a major impact on the biological response to various
particles, therefore, the particle specific surface modifica-
tion and the agents are an important factor that must be
considered when choosing particular NPs [6].
The valuable characteristics of AuNPs make them suita-
ble to act as plasmid DNA carriers and transfection enhan-
cers. Similarly, magnetic NPs loaded with the nucleic acid
of interest are used to increase transfection efficiency by
applying magnetic force to the DNA-NP complexes. These
magnetic DNA-NP complexes are drawn towards the
outer cell membrane via magnetic force and are subse-
quently taken up by the cell via endocytosis.
AuNPs can be generated using various methods, most
of which rely on chemical reactions or gas pyrolysis,
which carry the risk of agglomeration or contamination
with impurities such as citrate and residual precursors
like chloroauric acid [7].
Pulsed laser ablation in liquids (PLAL) has been
reported to present advantages in NP generation such as
low restriction for the choice of the source material
allowing the generation of highly pure colloidal particles
[8]. The generated pure AuNPs with the oxidation states
Au
+ and Au
+3 were reported to have a unique surface
chemistry and to be free of stabilizers, as a result of the
chemical composition of the liquid media used during
synthesis [8]. This inherent charge given to these AuNPs,
without adding a special coating that could have a poten-
tial cytotoxic effect make these NPs interesting for DNA-
binding and cell transfection. Previous studies demon-
strated that unmodified, circular, negatively charged DNA
molecules adsorb easily onto these positively charged NPs
[2]. Moreover, the incubation of these AuNPs with plas-
mid DNA did not alter the uptake of the vector through
the plasma membrane in presence of a transfection
reagent, and showed no apparent effect on the biological
activity of the produced recombinant protein [9]. How-
ever, although AuNP approaches have gained popularity,
the data concerning the toxic potential of these particles is
still marginal and the characterisation of the toxic poten-
tial of AuNPs in combination with complex DNA expres-
sion plasmids is mostly limited to model molecules.
Herein, we analysed the transfection efficiency and cyto-
toxicity of different NP-mediated transfection approaches
after the transfection of a mammalian cell line with two
different eukaryotic expression vectors encoding simulta-
neously for an expression protein (canine HMGB1 or
equine IL-12) and the humanized renilla Green Fluores-
cent Protein (hrGFP). Results were compared to those
obtained using a conventional standard transfection proto-
col (FuGENE HD, Roche, Mannheim, Germany).
Results
Transfection Efficiency
Fluorescence Microscopy
The uptake of plasmid DNA was primarily evaluated by
comparing the GFP positive cells to the total quantity of
cells showing blue DAPI fluorescence dye staining, thus
attaining an estimate of the transfection efficiency. After
24 h incubation, the transfection process both with the
plasmid DNA and with the transfection reagents alone
did not induce major negative effects on the cells. An
exception to this was the addition of the Plano-AuNP to
the cells, where 24 h post-transfectional cells showed
advanced apoptotic signs. The transfection efficiency of
cells transfected with the Plano-AuNP, PLAL-AuNP Size
1 and Size 2 protocol was apparently higher than that
achieved with the conventional FHD transfection reagent
or with the magnetic transfection protocols (MATra-A,
MA Lipofection) (Images not shown).
Flow cytometry analysis of GFP expression
The mean transfection efficiencies of the FHD transfection
were 16.22% and 31.52% for pIRES-hrGFPII-eIL-12
(Figure1; Table 1) and pIRES-hrGFPII-rHMGB1 (Figure 2;
Table 1), respectively.
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Page 2 of 11When AuNPs (Plano-AuNP and PLAL-AuNPs Size 1
and 2) were added, transfection efficiencies were signifi-
cantly increased for the pIRES-hrGFPII-eIL-12 vector,
reaching an almost two fold increase with PLAL-AuNPs
Size 2 and Plano-AuNP (FHD: 16.22%; PLAL-AuNPs
Size 2: 27.80%; Plano-AuNP: 28.01%; Figure 1; Table 1).
For the pIRES-hrGFPII-rHMGB1 vector a slighter but
still significant increase was observed when PLAL-
AuNPs Size 1 and 2 were applied (FHD: 31.52%, PLAL-
AuNPs_S1: 46.33%, PLAL-AuNPs_S2: 50.56%; Figure 2;
Table 1).
Toxicity Analyses
Flow cytometry analysis with propidium iodide staining
For the pIRES-hrGFPII-eIL-12 vector the mean propi-
dium iodide percentages (PI%) of each protocol were
similar to those reached by the cells transfected with the
conventional FHD protocol. An exception was the
Plano-AuNP protocol, showing a three-fold increase of
the mean PI% to 35.43% when compared to the FHD
protocol (9.69%; Figure 1; Table 2).
Transfection of the pIRES-hrGFPII-rHMGB1 vector
with the different protocols resulted in significantly
higher PI% using the PLAL-AuNPs_S1 and _S2. The
PLAL-AuNPs_S1 (PI 26.45%) showed a PI% nearly twice
that of the FHD protocol (13.75%; Figure 2; Table 2).
Proliferation Assay
The effect of the different transfection protocols on cell
vitality was investigated by determining cell proliferative
activity with a standard proliferation test (Cell Prolifera-
tion ELISA BrdU (colorimetric), Roche Diagnostics, Man-
nheim, Germany). The BrdU incorporation assayed 48 h
after transfection was significantly reduced when pIRES-
hrGFPII-eIL-12 was transfected using the Plano-AuNP
and the PLAL-AuNPs_S2 protocol. Seventy-two hours
after transfection, a decreased BrdU incorporation was
observed in the Plano-AuNP and in the FHD transfection
protocols (Figure 1; Table 3). The pIRES-hrGFPII-
rHMGB1 transfections showed a significantly reduction in
incorporation of BrdU 48 h after transfection using the
PLAL-AuNPs_S1 protocol. Similar results were observed
for the FHD and Plano-AuNP protocols 72 h post trans-
fection (Figure 2; Table 3).
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Figure 1 Transfection efficiency and toxicity of pIRES-hrGFPII-
eIL-12. GFP- (■) and PI- (◊) positive cells 24 h after transfection with
pIRES-hrGFPII-eIL-12. Mean cell proliferation (▲) (48 h and 72 h after
transfection with pIRES-hrGFPII-eIL-12). Each bar represents a mean ±
SD. * p ≤ 0.05.
Table 1 Transfection efficiency
pIRES-hrGFPII-eIL-12 pIRES-hrGFPII-rHMGB1
GFP % GFP %
FHD 16.22 ± 9.69 31.52 ± 4.33
Plano
®-AuNP 27.80 ± 3.90 * 22.93 ± 0.98 *
LAG-AuNP S1 28.01 ± 1.97 * 46.33 ± 2.07 *
LAG-AuNP S2 25.41 ± 2.22 * 50.56 ± 4.71 *
MA Lipofection 18.11 ± 0.60 22.29 ± 1.36 *
MATra-A 11.33 ± 1.30 16.24 ± 1.25 *
MTH53A Cells 1.98 ± 0.17 1.15 ± 0.56 *
GFP positive cells 24 h after transfection with pIRES-hrGFPII-eIL-12 or pIRES-
hrGFP-HMGB1. Results are expressed as mean ± SD. * p ≤ 0.05.
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Figure 2 Transfection efficiency and toxicity of pIRES-hrGFP-
rHMGB1. GFP- (■) and PI- (◊) positive cells 24 h after transfection
with pIRES-hrGFP-rHMGB1. Mean cell proliferation (▲) (48 h and 72 h
after transfection with pIRES-hrGFP-rHMGB1). Each bar represents a
mean ± SD. * p ≤ 0.05.
Table 2 Transfection toxicity
pIRES-hrGFPII-eIL-12 pIRES-hrGFPII-rHMGB1
PI % PI %
FHD 9.69 ± 2.92 13.75 ± 1.35
Plano
®-AuNP 35.43 ± 5.53 * 12.56 ± 3.72
LAG-AuNP S1 8.65 ± 1.24 26.45 ± 2.93 *
LAG-AuNP S2 7.92 ± 0.49 19.37 ± 4.28 *
MA Lipofection 5.56 ± 1.43 12.67 ± 1.33
MATra-A 13.6 ± 3.74 7.25 ± 0.29
MTH53A Cells 1.14 ± 0.17 1.01 ± 0.28
PI positive cells 24 h after transfection with pIRES-hrGFPII-eIL-12 or pIRES-
hrGFP-HMGB1. Results are expressed as mean ± SD. * p ≤ 0.05.
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Protein expression detection via immunofluorescence
Control cells showed only background staining, whereas
cells transfected with pIRES-hrGFPII-eIL-12 revealed a
diffuse accumulation of eIL-12 protein in the cytoplasm
and nuclei (Figure 3a-c). Cells transfected with pIRES-
hrGFPII-rHMGB1 showed a concentration of HMGB1
protein located in the nuclei (Figure 3d-f). Transfection
of the cells with the pIRES-hrGFPII-eIL-12 or the
pIRES-hrGFPII-rHMGB1 vector led to the expression of
biological functional recombinant proteins localized in
their final destination.
The transfections using both gold NP and Ma Lipofec-
tion protocols in combination with pIRES-hrGFPII-
rHMGB1 showed a HMGB1 protein expression similar
to the FHD protocol (Figure 4).
Discussion
Advances in immunology and cancer research would
benefit from improved transfection efficiencies, high
reproducibility and low toxicity of the required transfec-
tion approach. High transfection efficiency for plasmid
DNA delivery into cells is still an important issue in
gene therapy. Thus, a number of different approaches
have been used to increase efficiency [10-12]. Unfortu-
nately, the majority of the studies involving transfection
of mammalian cells with non-viral vectors primarily
assess transfection efficiency, lacking toxicity data.
Therefore, the present study compared several NP-
mediated transfection protocols in which plasmid DNA
vectors were transfected into a mammalian cell line and
the transfection efficiency and cytotoxicity of each pro-
tocol was analysed after transfection.
The addition of AuNPs (PLAL-AuNPs_S1 and _S2
and Plano-AuNPs) to the pIRES-hrGFPII-eIL-12 trans-
fection protocols significantly increased transfection effi-
ciency (FHD: 16%; AuNP transfection efficiency mean:
28%; p = 0.05). Compared to this, the magnet-assisted
protocols did not improve the transfection efficiency of
pIRES-hrGFPII-eIL-12, resulting in values similar to the
FHD protocol. An increase of the transfection efficiency
for the pIRES-hrGFPII-rHMGB1 was only detectable
with the PLAL-AuNPs (FHD: 31%; PLAL-AuNPs_S1:
46%; PLAL-AuNPs_S2: 50%; p = 0.05). As for pIRES-
hrGFPII-eIL-12, with the recombinant pIRES-hrGFPII-
rHMGB1 vector no improvement of transfection effi-
ciency was achieved through the use of the magnet-
assisted transfection protocols. On the contrary, the effi-
ciency was significantly lower when compared to the
conventional FHD protocol.
Remarkably, the AuNP-mediated transfection efficien-
cies achieved in this study are higher than those
reported by Schakowski et al. (2001) [12] in which a
colon carcinoma cell line was transfected with minimal
size gene transfer (MIDGE) vectors and corresponding
plasmids (containing coding sequences for eGFP or
human IL-2). Here, the transfection efficiency was up to
36% (MIDGE Vectors) and 33% (plasmid vectors)
respectively [12]. A previous study by Petersen et al.
(2009) [2] reported an apparent increase of the transfec-
tion rates when the biocompatibility of PLAL-AuNPs
was analysed. The transfection reactions with plasmid
DNA and PLAL-AuNPs of different hydrodynamic size
classes (14, 24, 59 and 89 nm) showed transfection effi-
ciencies ranging from 10 to 60%, reaching the highest
efficiency using a NP size of 59 nm [2]. With regard to
the many potential applications of these PLAL-AuNPs
in the fields of research and therapy, the promising
results described above indicated the necessity of analys-
ing the definitive transfection efficiencies and the possi-
ble cytotoxicity of PLAL-AuNPs. Two of the former
four PLAL-AuNPs size classes were selected for our
experiments based on the results of Petersen et al.[ 2 ] .
The chosen AuNP sizes should be considered relevant
to the transfection outcome. The results of Chithrani et
al. [13] showed that for mammalian cells (HeLa) the
maximum uptake of spherical and rod-shaped AuNPs,
in a size range of 10-100 nm (fully or partially modified
by citric acid ligands), was reached with the 50 nm
AuNPs (Feret diameter).
Table 3 Cell proliferation after transfection
pIRES-hrGFPII-eIL-12 pIRES-hrGFPII-rHMGB1
48 h 72 h 48 h 72 h
FHD 172.57 ± 53.44 111.06 ± 18.72* 201.13 ± 52.57 91.23 ± 1.04*
Plano
®-AuNP 72.99 ± 39.32* 64.65 ± 14.19* 154.49 ± 28.71 83.81 ± 8.34*
LAG-AuNP S1 126.19 ± 41.31 174.86 ± 18.54 103.00 ± 21.84* 193.48 ± 14.05
LAG-AuNP S2 98.95 ± 25.09* 200.93 ± 7.52 140.53 ± 30.20 196.35 ± 15.79
MALipofection 132.24 ± 21.05 153.30 ± 12.38 153.17 ± 47.41 179.62 ± 24.20
MATra-A 165.15 ± 42.89 145.88 ± 40.31 143.72 ± 22.50 153.77 ± 13.07
MTH53A Cells 191.84 ± 25.75 188.01 ± 20.11 185.07 ± 21.15 178.11 ± 21.01
Cell proliferation 48 h and 72 h after transfection with pIRES-hrGFPII-eIL-12 or pIRES-hrGFP-HMGB1. Results are expressed as mean absorbance values ± SD. * p ≤
0.05.
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constructs used in our study were similarly affected by
the different protocols applied. The overall higher trans-
fection efficiencies attained using the pIRES-hrGFPII-
rHMGB1 vector could be explained due to the different
vector and insert sizes. The pIRES-hrGFPII-rHMGB1
vector has a size of 5531 bp whereas pIRES-hrGFPII-
eIL-12 has a molecular length of 7709 bp. Such size
mediated effects in transfections were studied by Yin
et al. (2005) [14]. They demonstrated an inverse correla-
tion between the construct size and the promoter/
enhancer activity measured by the dual luciferase system
in a transient transfection assay of mammalian cells.
Larger plasmid or recombinant plasmid constructs
resulted in lower transfection efficiencies than when
smaller ones were used [14].
In the present study, in contrast to our expectation, the
magnet-assisted protocols using magnetic nanoparticle-
mediated DNA-uptake did not increase the transfection
ratio of pIRES-hrGFPII-eIL-12, resulting in transfection
efficiencies and PI% comparable to those achieved by the
FHD protocol. When pIRES-hrGFPII-rHMGB1 was trans-
fected, the efficiency was significantly lower than that
reached with the conventional FHD protocol, but with sig-
nificantly lower toxicity results. A study by Bertram [3]
suggested that the directed delivery of the cargo (e.g.
DNA) towards the cells applying magnet-assisted transfec-
tion technology may increase the overall transfection effi-
ciency depending on the cell type used. Although an
improvement of the transfection efficiency could not be
observed using the magnet-assisted protocol, it is impor-
tant to highlight that as published by Renker et al. [15], in
our study, when pIRES-hrGFPII-rHMGB1 was transfected
using the MATra-A transfection protocol, a significantly
low PI% and a cell proliferation similar to non-transfected
control cells was detected. This attribute of the MATra-A
protocol should be taken into consideration when gentler
transfection methods on sensitive cells are required.
The protein expression results for canine HMGB1 and
eIL-12 show that the protein expression is sufficient.
After transfection, the expression of simple proteins as
GFP and the nuclear acting HMGB1 and of complex
proteins consisting of two separate subunits as IL-12 is
possible. Furthermore, the addition of NP or magnetic
reagent to the pIRES-hrGFPII-rHMGB1 transfections
did not interfere with protein expression as shown in
Figure 4.
Even though the use AuNPs improved the transfection
efficiency achieved in this study, the required amount of
reagent and type of enhancers (e.g. AuNPs) must be
considered specifically for each cell type and vector in
order to achieve an appropriate recombinant vector
Figure 3 Immunofluorescence 24 h after transfection. pIRES-hrGFPII-eIL-12 transfection with the FHD protocol, primary antibody goat IgG
anti-p35 and a donkey anti-goat secondary antibody (Texas Red fluorochrome). (a) GFP and Red Fluorescence merged image, (b) GFP
Fluorescence and (c) Red Fluorescence images. Scale bar 50 μm. pIRES-hrGFP-HMGB1 transfection with the FHD protocol, primary antibody
mouse anti-HMGB1 and secondary antibody goat anti-mouse (Texas Red fluorochrome). (d) GFP and Red Fluorescence merged image, (e) GFP
Fluorescence and (f) Red Fluorescence images. Scale bar 75 μm.
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potential benefits of the AuNPs described, the safety of
their use in biological organisms has to be evaluated in
full. In this study, when the pIRES-hrGFPII-eIL-12 vec-
tor was transfected, the addition of the ligand-free
PLAL-AuNPs (S1 and S2) had no significant toxic effect
on the cells. Nevertheless, when commercially purchased
poly-L-lysine-coated colloidal gold NPs (Plano-AuNP)
were applied, an increased PI% and decreased cell prolif-
eration could be observed confirming a toxic effect of
these particle formulations on cell vitality. For the
pIRES-hrGFPII-rHMGB1 transfections a significantly
higher PI% was measured when PLAL-AuNPs (S1 and
S2) were applied. This was not supported by the cell
proliferation analysis where a NP-mediated toxic effect
was observed neither 48 h nor 72 h after transfection.
The potential toxicity of AuNPs has been an issue in
previous studies [4,16-18]. Recently, the uptake of ligand-
free positively charged gold NPs during coincubation with
a bovine cell line (GM7373) occurred apparently by diffu-
sion [19]. At the same time, the assessment of cell mor-
phology, membrane integrity, and apoptosis revealed no
AuNP-related loss of cell vitality at gold concentrations of
25 μM or below, and no cytotoxic effect was observed in a
proliferation assay after exposing low cell numbers to the
same PLAL-AuNP concentrations [19]. Interestingly, cell
proliferation was reduced when cells were coincubated
with ligand-free gold NPs concentrations of 50 μMa n d
above [19]. Although, AuNP cytotoxicity was not the aim
of the study by Petersen et al. [2], they observed that the
PLAL-AuNP application apparently had no cytotoxic
effect, since normal cell density and appearance in all set
ups was similar prior- and posttransfectional. In this con-
text, Shukla et al. (2005) [20] concluded that chemically
synthesized AuNPs (35 ± 7 Å in size, Feret diameter) are
inert and nontoxic to the cells and that no stress-induced
Figure 4 Immunofluorescence 24 h after NP-mediated transfection. pIRES-hrGFP-HMGB1 transfection with NP-mediated protocols. Plano-
AuNP (a, b, c), PLAL-AuNP Size 2 (d, e, f), and MA Lipofection (g, h, i)). Primary antibody: mouse anti-HMGB; secondary antibody: goat anti-
mouse (Texas Red fluorochrome). a, d, g: GFP and Red Fluorescence merged image; b, e, h: GFP Fluorescence and (c, f, i) Red Fluorescence
images. Scale bar 75 μm.
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Page 6 of 11secretion of proinflammatory cytokines as TNF-a and IL-
1b by macrophage cells (RAW264.7) was detectable.
In our study, the average PI% of the transfected cells
(12.3% for pIRES-hrGFPII-eIL-12; 13.9% for pIRES-
hrGFPII-rHMGB1) can be compared with the 10-20%
reported by Schakowski et al. [12] after the transfection of
a colon carcinoma cell line with plasmid and MIDGE vec-
tors. Regarding the size of NPs in relation to cell toxicity,
Pernodet et al. (2006) [21] demonstrated that 13 nm
AuNPs (Feret diameter) generate apoptosis and morpholo-
gical deformation at 2-6 days in CF-31 human dermal
fibroblast cells. Additionally, Pan et al. (2007) [16] reported
that AuNPs with a diameter of 2 nm or less (Feret dia-
meter) were cytotoxic for different cell lines (termed HeLa,
SK-Mel28, L929 mouse fibroblasts and J774A1 mouse
monocytic/macrophage cells), whereas 15 nm AuNPs were
nontoxic to the cells. These NP size dependent results
could be due to the larger surface area per unit mass of
smaller sized NPs. Related to this, particle toxicology sug-
gests that, for toxic particles generally, more particle sur-
face equals more toxicity [6].
Interestingly, the significant toxicity we observed when
using the 20 nm Plano-AuNP (with pIRES-hrGFPII-eIL-
12) differs from the recent study by Brandenberger et al.
[22]. They applied similar commercially available aqueous
colloidal AuNPs, 15 nm in size and coated with poly-L-
lysine. The AuNPs entered the cells, but no cytotoxic
effects of these AuNPs were observed [22]. These results
suggest that possibly the poly-L-lysine coating does not
induce a direct toxic effect on cells, although impurities in
the AuNP colloid formulations are supposed to increase
the toxicity compared to pure AuNPs.
The results presented herein suggest that further use of
each protocol should be evaluated under consideration of
the transfection efficiency results together with the toxi-
city results. To do so, we subtracted the PI% from the
total number of GFP positive cells (Figure 5). For the
pIRES-hrGFPII-eIL-12 transfections, this calculation
showed that even though the Plano protocol generated
almost the highest transfection efficiency, the outcome
was not as good when considered in combination with
the cell toxicity results. In contrast, the PLAL-AuNP_S1
protocol provided the best overall (combined) results.
For the pIRES-hrGFPII-rHMGB1 transfections the use of
the PLAL-AuNPs_S2 protocol showed the highest effi-
ciency and just a slightly increased toxicity, making this
protocol the one with the best final outcome.
Hence, both test series (Figure 1 and 2, Table 1) indicate
that AuNPs, in particular the physically made pure col-
loids, are able to significantly increase transfection effi-
ciency and that a trade-off in cell vitality becomes
significant in particular with the chemically made AuNPs.
The residual nanoparticle ligands of these NPs may play
an unintended, yet underestimated role in NP-mediated
cellular uptake. However, further studies with different cell
lines and expression vectors should be performed to
be able to decide if the observed cytotoxic effects can
be explained by simple NP cell intolerance or by incom-
patibility of the cells with the transfected recombinant vec-
tor or the expressed recombinant protein.
Conclusions
Transfection efficiency of plasmid DNA vectors can be
s i g n i f i c a n t l yi m p r o v e db yt h ea d d i t i o no fl i g a n d - f r e e
PLAL-AuNPs (29 nm and 52 nm in size) to conven-
tional transfection reagents like FuGENE HD. Cell vital-
ity was negatively affected mainly by the addition of
chemically generated AuNPs (Plano-AuNPs), but also
slightly by physically made AuNPs (PLAL-AuNPs_S1)
resulting in increased cytotoxic effects and reduction of
cell proliferation. Among the transfection methods
investigated comparatively in this study, 29 nm AuNPs
made by PLAL span the widest window in terms of high
transfection efficiency with minimized trade-off in
vitality.
Methods
Mammalian expression vectors
Two different mammalian expression vectors simulta-
neously encoding for an expression protein (canine
HMGB1 (HMGB1) or equine IL-12 (eIL-12)) and the
hrGFP were constructed. The expression of the inserted
genes of interest can be assessed by the simultaneous
but separate expression of hrGFP due to a bicistronic
Figure 5 Vital cells after transfection. Number of vital MTH53A
cells (GFP positive cells minus PI positive cells) 24 h after
transfection with pIRES-hrGFP-eIL12 (□) or pIRES-hrGFP-rHMGB1 (■).
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plasmids used here. Accordingly, the successful transfec-
tion of the cells may be analysed using GFP-based fluor-
escence microscopy as well as flow cytometry. The used
vectors differ in that, apart from the GFP, the HMGB1
vector encodes a single chain protein, while the IL-12
vector encodes a complex protein consisting of two dif-
ferent subunits which are posttranslationally processed
by the cell to a joint complex. Thus, a successful assem-
bling of recombinant IL-12 is dependent on the ability
of the transfected cell to correctly process complex post-
translational protein modifications.
PIRES-hrGFPII-eIL-12
DNA encoding for eIL-12 (Vetsuisse-Faculty, University of
Zurich) was amplified by PCR (primer pair: NotI_IL-12_f
5’-CGGCGGCCGCATATGTGCCCGCCGCGC-3’ (for-
ward primer); NotI_IL-12_r 5’-CGGCGGCCGCAACTG-
CAGGATACGG-3’ (reverse primer)). The DNA contains
the p35 and p40 IL-12 subunit cDNAs (p35: Acc. No.
Y11129; p40: Acc. No. Y11130) separated by an IRES ele-
ment, both IL-12 subunits are translated separately and
then processed by the cell to a joint complex. The PCR
products were separated on a 1.5% agarose gel, eluted
using QIAquick Gel Extraction Kit (QIAGEN, Hilden,
Germany), and cloned into the bicistronic pIRES-hrGFPII
mammalian expression vector (Stratagene, La Jolla, CA,
USA). Verification of the constructed plasmid was done by
NotI restriction digest and sequencing.
PIRES-hrGFPII-rHMGB1
For construction of the pIRES-hrGFPII-rHMGB1 expres-
sion plasmid, the canine HMGB1 coding sequence (Acc.
No. AY135519) without the terminal stop codon was
inserted into the bicistronic pIRES-hrGFP II vector (Stra-
t a g e n e ,L aJ o l l a ,C A ,U S A ) .E x p r e s s i o no ft h ei n s e r t e d
HMGB1 coding sequence results in an HMGB1 fusion
protein with a recombinant short 3 × FLAG peptide
sequence at its C-terminal part (rHMGB1).
The following primer pair was used for PCR-amplifica-
tion: EcoRI-B1-CFA-Fwd (5’-GGAATTCCACCATGGG-
CAAAGGAGA-3’;f o r w a r dp r i m e r )a n dN o t I - B 1 - C F A -
Rev/-TAA (5’-AAGAATGATGATGATGAAGCGGCC
GCGC-3’, reverse primer).
The amplified PCR product was separated on a 1.5%
agarose gel, purified using QIAquick Gel Extraction Kit
(QIAGEN, Hilden, Germany) and ligated into the
pIRES-hrGFPII vector plasmid (Stratagene, La Jolla,
CA). Verification of the constructed plasmid was done
by NotI/EcoRI double restriction digest and sequencing.
Cell culture and in vitro transfection assays
The MTH53A canine mammary cell line used for the
experiments was derived from epithelial healthy canine
mammary tissue.
Eight hours prior to the transfection, 3 × 10
5 MTH53A
cells were seeded in 6-well plates with 2 ml cell culture
medium. The cells were grown as adherent cultures in a
humidified atmosphere at 37°C and 5% CO2 in complete
medium 199 (medium 199; Invitrogen, Karlsruhe, Ger-
many) supplemented with 10% heat-inactivated fetal calf
serum (PAA Laboratories GmbH, Pasching, Austria),
200 U/ml penicillin and 200 ng/ml streptomycin (Bio-
chrom AG, Berlin, Germany)).
For transfection the following different protocols were
applied in triplicate
1) FHD: 5 μL of FuGENE HD (FHD, Roche, Mannheim,
Germany) were added to 2 μg of pIRES-hrGFPII-eIL-12
or pIRES-hrGFPII-rHMGB1 at a total volume of 100 μL
ddH2O, incubated for 10 minutes at room temperature
and added to the seeded cells.
2) Plano-AuNP (EM CGC20, 20 nm; Plano GmbH,
Wetzlar, Germany): 20 μL of Plano-AuNP were incu-
bated for 24 h at room temperature with 2 μg of pIRES-
hrGFPII-eIL-12 or pIRES-hrGFPII-rHMGB1 at a total
volume of 95 μL ddH2O. For transfection 5 μLa l i q u o t s
of FHD reagent (Roche, Mannheim, Germany) were
added to 95 μL of the AuNP /vector suspension, incu-
bated for 10 minutes at room temperature and added to
cell cultures.
3) PLAL-AuNP size 1 (d50 = 28.5 nm and d90 = 43.4
nm hydrodynamic sizes; 14 ± 3 nm Feret diameter (Figure
6)) and size 2 (d50 = 52.4 nm and d90 = 78.6 nm hydrody-
namic sizes; 41 ± 8 nm Feret diameter (Figure 6)): The
PLAL-AuNP suspensions were sterilized by filtration
through a 0.2 μm filter device (Millex-GV Sterilizing Filter
Unit, Millipore, Billerica, USA). Subsequently, 20 μLo f
each sized AuNPs were incubated for 24 h at room tem-
perature with 2 μg of pIRES-hrGFPII-eIL-12 or pIRES-
hrGFPII-rHMGB1 at a total volume of 95 μLo fd d H 2O.
For transfection 5 μL aliquots of FHD reagent (Roche,
Mannheim, Germany) were added to 95 μLo ft h eA u N P
/vector suspension, incubated for 10 minutes at room
temperature and added to cell cultures.
3.1) Nanoparticle generation: AuNPs were generated by
pulsed laser ablation in liquid (PLAL) [9]. The beam of a
femtosecond laser system (Spitfire Pro, Spectra-Physics),
delivering 120 fs laser pulses at a wavelength of 800 nm
was focused with a 40 mm lens on a 99.99% pure gold tar-
get placed at the bottom of a Petri dish filled with 2 mL of
ddH2O. Pulse energy of 200 μJ at 5 kHz repetition rate
was employed for 12 minutes of irradiation. The target
position was set 4 mm or 2 mm below the determined
focal point in air, in order to obtain colloidal suspensions
containing AuNPs with mean hydrodynamic diameters of
dh = 29 nm (size 1) and dh = 52 nm (size 2), respectively.
The remaining small particles were removed by centrifu-
gation. Characterisation of NP colloids was performed by
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by UV-Vis spectroscopy using a Shimadzu 1650.
4) Magnet-assisted transfection: (MA Lipofection &
MATra-A):
4.1) MA Lipofection: 5 μL of FHD (Roche, Mannheim,
Germany) were added to 2 μg of pIRES-hrGFPII-eIL-12 or
pIRES-hrGFPII-rHMGB1 to a total volume of 97 μL
ddH2O and incubated for 10 minutes at room tempera-
ture. Afterwards, 3 μL of MA Lipofection enhancer (Pro-
moKine, Heidelberg, Germany) were added and incubated
at room temperature for 15 minutes.
4.2) MATra-A: 3 μL of the magnetic reagent MATra-
A (PromoKine, Heidelberg, Germany) were added to 2
μg of pIRES-hrGFPII-eIL-12 or pIRES-hrGFPII-rHMGB1
to a total volume of 97 μL of complete medium 199
(without FCS) and incubated for 15 minutes at room
temperature.
For MATra-A and MA Lipofection, after final incuba-
tion, the 100 μL suspension was added to the cell cultures
and each of the 6-well plates were placed on a magnetic
plate at 37°C and 5% CO2 for 15 minutes (Universal Mag-
net Plate; PromoKine, Heidelberg, Germany). Afterwards,
the plate was removed.
After each transfection, cells were incubated for 24
hours in complete medium 199 at 37°C and 5% CO2.
For each protocol the incubation of cells with the
transfection reagents and without DNA was considered
as the negative control.
The plasmid DNA uptake of pIRES-hrGFPII-eIL-12 and
pIRES-hrGFPII-rHMGB1 was verified by fluorescence
microscopy and measured by flow cytometry (FACSCali-
bur flow cytometer).
Each protocol was performed in triplicate.
Results are expressed as means.
Figure 6 Size distribution of pulsed laser ablation in liquid generated AuNPs. Size distribution (Feret diameter) of PLAL-AuNP size 1
(hydrodynamic sizes: d50 = 28.5 nm and d90 = 43.4 nm, Feret diameter: 14 ± 3 nm) and size 2 (hydrodynamic sizes: d50 = 52.4 nm and 90 =
78.6 nm, Feret diameter: 41 ± 8 nm).
Durán et al. Journal of Nanobiotechnology 2011, 9:47
http://www.jnanobiotechnology.com/content/9/1/47
Page 9 of 11Transfection Efficiency Analyses
Fluorescence Microscopy
Transfected cells were fixed in a 4% paraformaldehyde/
PBS solution for 15 minutes at room temperature. After
fixation 10 μL of Vectashield Mounting Medium with
DAPI (4’-6-diamidino-2-phenylindol, Vector Labora-
tories, Burlingame, CA, USA) was applied for fluores-
cent visualization of nucleic DNA. Fluorescence
microscopy was performed using an Axio Imager. Z1
fluorescence microscope (Carl Zeiss MicroImaging
GmbH, Jena, Germany) and images were recorded using
the AxioVision Software (Rel. 4.7). The hrGFP fluores-
cence was measured employing wavelength filter set 10
(Carl Zeiss MicroImaging, Goettingen, Germany), while
DAPI fluorescence was measured employing wavelength
filter set 2.
Flow cytometry
GFP expression of the transfected cells was analysed mea-
suring green fluorescence by flow cytometry in order to
determine the transfection efficiency of each protocol.
Cells were trypsinized for 3-5 min, washed with PBS,
resuspended in the medium, and measured with a FACS-
can flow cytometer (Becton, Dickinson and Company,
Heidelberg, Germany). Fluorescence intensities were ana-
lysed with Cell Quest software (Becton, Dickinson and
Company, Heidelberg, Germany). The percentage of posi-
tive cells was assessed comparing dot plot analysis of the
transfected cells to cells incubated only with transfection
reagent with or without the addition of NPs (depending of
the protocol used).
Results are expressed as percentage of positive cells, as
indicator for transfection efficiency.
The transfection efficiency results of each protocol
were finally compared with those of the conventional
FHD protocol.
Toxicity Analyses
Flow cytometry
Propidium iodide (PI) staining was used to identify the cell
death percentage after transfection. Cells were trypsinized,
resuspended in complete medium 199 and PI (5 μg/mL)
was added. The cytometry analysis was performed using a
FACSCalibur device (Becton, Dickinson and Company,
Heidelberg, Germany) with Cell Quest software (Becton,
Dickinson and Company, Heidelberg, Germany). There-
after, the cells were assessed for PI florescence by dot plot
analysis and compared to cells incubated only with trans-
fection reagent with or without the addition of NPs
(depending of the protocol used).
Results are expressed as percentage of positive cells
The toxicity results of each protocol were compared
with those of the conventional FHD protocol.
Proliferation Assay
Proliferation of cells in response to each transfection pro-
tocol was evaluated using a colorimetric cell proliferation
ELISA (Roche Applied Science, Mannheim, Germany)
which measures the incorporation of 5-bromo-2-deoxyuri-
dine (BrdU), a thymidine analogue, into DNA by ELISA
using an anti-BrdU monoclonal antibody.
Eight hours prior to transfection, 1.5 × 10
4 MTH53A
cells were placed in 96-well plates. Cells were grown at 37°
Ca n d5 %C O 2 in complete medium 199 (Invitrogen,
Karlsruhe, Germany) supplemented with 10% heat-inacti-
vated FCS (PAA Laboratories GmbH, Pasching, Austria),
200 U/ml penicillin and 200 ng/ml streptomycin (Bio-
chrom AG, Berlin, Germany). Each protocol was per-
formed in triplicate as explained above. The proliferation
assay was carried out according to manufacturer’s recom-
mendations (Cell proliferation ELISA, colorimetric, Cat.
No. 11647229001, Roche Applied Science, Mannheim,
Germany). The reaction products were quantified by mea-
suring the absorbance at 370 nm (reference wavelength
492 nm) using a scanning multiwell spectrophotometer
equipped with the analysis software Gen 5 (Synergy HT
multi-mode microplate reader, BioTek Instruments Inc.,
Bad Friedrichshall Germany). The absorbance results
directly correlate to the amount of DNA synthesis and
hereby to the number of proliferating cells.
Results are expressed as mean absorbance values
The proliferation results of each protocol were com-
pared to those of non-transfected cells.
Protein Expression
To confirm biological functionality of the expressed pro-
teins, immunofluorescence directed against eIL-12 and
canine HMGB1 was performed after transfection.
Equine IL-12
The expression of eIL-12 was evaluated in MTH53A cells.
Eight hours prior to transfection 3 × 10
5 MTH53A cells
were seeded in 6-well plates. Cells were grown under stan-
dard conditions as described above. Transfection was per-
formed as explained for the FHD protocol. Subsequently,
24 h after transfection cells were fixed in a 4% paraformal-
dehyde/PBS solution for 20 minutes at room temperature,
permeabilized and blocked. Immunofluorescence was per-
formed using a goat IgG anti-p35 polyclonal primary anti-
body (IL-12 p35, sc-1280, Santa Cruz Biotechnology, Inc.;
Santa Cruz, CA, USA; dilution 1:40) and a donkey anti-
goat secondary antibody (IgG-TR, sc-2783; Santa Cruz
Biotechnology, Inc.; Santa Cruz, CA; dilution 1:180).
Fluorescence microscopy was carried out using a Leica
DMI 6000 fluorescence microscope (Leica Microsystems
GmbH, Wetzlar Germany).
Canine HMGB1
The expression of HMGB1 was also evaluated in
MTH53A cells. Cells were prepared as described for the
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with four different protocols (FHD, Plano-AuNP, PLAL-
AuNP_S2 and Ma Lipofection), immunofluorescence
was performed using an anti-HMGB1 mouse monoclo-
nal antibody (HMGB1 antibody [HAP46.5], ab12029-
100, Abcam, Cambridge, UK; 1:60) and a goat anti-
mouse antibody (DyLight™ 549-TFP ester, Code Nr.
115-505-062, Jackson ImmunoResearch, West Grove,
PA, USA; dilution 1:220). Fluorescence microscopy was
also performed as described above.
Statistics
Results are presented as mean ± standard deviation. Sta-
tistical significance was determined using the 1-tailed
Wilcoxon-Mann-Whitney test. Differences were consid-
ered statistically significant for p ≤ 0.05.
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